Journal of Hospice and Palliative Care

Korean Society for Hospice and Palliative Care (한국호스피스완화의료학회)
권호 표지

Symptom Management for Cancer Patients

암환자 증상 관리와 연구 동향

  • Received : 2012.05.21
  • Accepted : 2012.05.22
  • Published : 2012.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Ministry of Health & Welfare, Korea Central Cancer Registry, National Cancer Center, editors. Annual report of cancer statistics in Korea in 2009 [Internet]. Seoul: Ministry of Health & Welfare; 2012 [cited 2012 Jan 2]. Available from: http://cancer.go.kr/nciapps/fcatalog/ecatalog.jsp?Dir=92.
  2. Yun YH, Rhee YS, Nam SY, Park SM, Lee JS, Park MH, et al. The socioeconomic impact of terminal cancer on patients' families and its associated factors. J Korean Acad Fam Med 2005;26:31-9.
  3. Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, et al. National Institutes of Health State-of-the-Science Conference Statement: symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst 2003;95:1110-7. https://doi.org/10.1093/jnci/djg014
  4. Cleeland CS, Fisch MJ, Dunn AJ. Cancer symptom science: measurement, mechanism, and management. 1st ed. New York: Cambridge University Press;2011.
  5. Lee MA, Yeom CH, Choi YS, Jang SK, Park J, Song CH, et al. The frequency and distress score of symptom of cancer patients - for the development of Korean Cancer Pain Assessment Tool (K-CPAT). Korean J Hosp Palliat Care 2003;6:45-50.
  6. Chen ML, Tseng HC. Symptom clusters in cancer patients. Support Care Cancer 2006;14:825-30. https://doi.org/10.1007/s00520-006-0019-8
  7. Miaskowski C, Aouizerat BE, Dodd M, Cooper B. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr 2007;(37):39-46.
  8. Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008;113:2102-9. https://doi.org/10.1002/cncr.23820
  9. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-11. https://doi.org/10.1097/00006842-200207000-00010
  10. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 1998;9:99-106. https://doi.org/10.1615/CritRevOncog.v9.i2.10
  11. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
  12. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, et al. The Val158Met polymorphism of the humancatechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73-8. https://doi.org/10.1016/j.pain.2005.03.032
  13. Ross JR, Riley J, Taegetmeyer AB, Sato H, Gretton S, du Bois RM, et al. Genetic variation and response to morphinein cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008;112:1390-403. https://doi.org/10.1002/cncr.23292
  14. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Monogr 2007;(37):16-21.
  15. Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okuyama T, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst 2010;102:732-8. https://doi.org/10.1093/jnci/djq097
  16. Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, et al. Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology 2004;66:439-44. https://doi.org/10.1159/000079497
  17. Yun YH, Wang XS, Lee JS, Roh JW, Lee CG, Lee WS, et al. Validation study of the Korean version of the brief fatigue inventory. J Pain Symptom Manage 2005;29:165-72. https://doi.org/10.1016/j.jpainsymman.2004.04.013
  18. Yun YH, Mendoza TR, Kang IO, You CH, Roh JW, Lee CG, et al. Validation study of the Korean version of the M. D. Anderson Symptom Inventory. J Pain Symptom Manage 2006;31:345-52. https://doi.org/10.1016/j.jpainsymman.2005.07.013
  19. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, et al. Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004;13:863-8.
  20. Shin DW, Choi JE, Miyashita M, Choi JY, Kang J, Baik YJ, et al. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 15-Palliative Care. J Pain Symptom Manage 2011;41:478-84. https://doi.org/10.1016/j.jpainsymman.2010.05.009
  21. Choi YS, Lee J, Park JN, Lee MA, Yeom CH, Jang SK. Reliability and validity of the evaluation of Korean Cancer Pain Assessment Tool (K-CPAT). Korean J Hosp Palliat Care 2003;6:152-63.
  22. Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The roleof bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998;78:157-69. https://doi.org/10.1016/S0304-3959(98)00135-3
  23. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-4.